This report contains market size and forecasts of Non-Cancerous Blood Disease Treatment in Global, including the following market information:
Global Non-Cancerous Blood Disease Treatment Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Non-Cancerous Blood Disease Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Antibiotics Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Non-Cancerous Blood Disease Treatment include SANOFI, Novo Nordisk A/S, Novartis AG, Pfizer Inc., Amgen Inc., Alexion Pharmaceuticals, Inc., Bayer AG, Bristol Myers Squibb Company and F. Hoffmann-La Roche Ltd., etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-Cancerous Blood Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Cancerous Blood Disease Treatment Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Non-Cancerous Blood Disease Treatment Market Segment Percentages, by Type, 2022 (%)
Antibiotics
Blood Transfusion
Infusion Therapy
Dietary Supplements or Chelators
Others
Global Non-Cancerous Blood Disease Treatment Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Non-Cancerous Blood Disease Treatment Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Non-Cancerous Blood Disease Treatment Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Non-Cancerous Blood Disease Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Cancerous Blood Disease Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-Cancerous Blood Disease Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
SANOFI
Novo Nordisk A/S
Novartis AG
Pfizer Inc.
Amgen Inc.
Alexion Pharmaceuticals, Inc.
Bayer AG
Bristol Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Takeda Pharmaceutical Company Limited
CSL Behring
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-Cancerous Blood Disease Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Cancerous Blood Disease Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Cancerous Blood Disease Treatment Overall Market Size
2.1 Global Non-Cancerous Blood Disease Treatment Market Size: 2022 VS 2030
2.2 Global Non-Cancerous Blood Disease Treatment Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Cancerous Blood Disease Treatment Players in Global Market
3.2 Top Global Non-Cancerous Blood Disease Treatment Companies Ranked by Revenue
3.3 Global Non-Cancerous Blood Disease Treatment Revenue by Companies
3.4 Top 3 and Top 5 Non-Cancerous Blood Disease Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-Cancerous Blood Disease Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Cancerous Blood Disease Treatment Players in Global Market
3.6.1 List of Global Tier 1 Non-Cancerous Blood Disease Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Cancerous Blood Disease Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Non-Cancerous Blood Disease Treatment Market Size Markets, 2022 & 2030
4.1.2 Antibiotics
4.1.3 Blood Transfusion
4.1.4 Infusion Therapy
4.1.5 Dietary Supplements or Chelators
4.1.6 Others
4.2 By Type - Global Non-Cancerous Blood Disease Treatment Revenue & Forecasts
4.2.1 By Type - Global Non-Cancerous Blood Disease Treatment Revenue, 2018-2023
4.2.2 By Type - Global Non-Cancerous Blood Disease Treatment Revenue, 2023-2030
4.2.3 By Type - Global Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-Cancerous Blood Disease Treatment Market Size, 2022 & 2030
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Non-Cancerous Blood Disease Treatment Revenue & Forecasts
5.2.1 By Application - Global Non-Cancerous Blood Disease Treatment Revenue, 2018-2023
5.2.2 By Application - Global Non-Cancerous Blood Disease Treatment Revenue, 2023-2030
5.2.3 By Application - Global Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Non-Cancerous Blood Disease Treatment Market Size, 2022 & 2030
6.2 By Region - Global Non-Cancerous Blood Disease Treatment Revenue & Forecasts
6.2.1 By Region - Global Non-Cancerous Blood Disease Treatment Revenue, 2018-2023
6.2.2 By Region - Global Non-Cancerous Blood Disease Treatment Revenue, 2023-2030
6.2.3 By Region - Global Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Non-Cancerous Blood Disease Treatment Revenue, 2018-2030
6.3.2 US Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.3.3 Canada Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.3.4 Mexico Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Non-Cancerous Blood Disease Treatment Revenue, 2018-2030
6.4.2 Germany Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.4.3 France Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.4.4 U.K. Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.4.5 Italy Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.4.6 Russia Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.4.7 Nordic Countries Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.4.8 Benelux Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Non-Cancerous Blood Disease Treatment Revenue, 2018-2030
6.5.2 China Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.5.3 Japan Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.5.4 South Korea Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.5.5 Southeast Asia Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.5.6 India Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Non-Cancerous Blood Disease Treatment Revenue, 2018-2030
6.6.2 Brazil Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.6.3 Argentina Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Cancerous Blood Disease Treatment Revenue, 2018-2030
6.7.2 Turkey Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.7.3 Israel Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.7.4 Saudi Arabia Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
6.7.5 UAE Non-Cancerous Blood Disease Treatment Market Size, 2018-2030
7 Players Profiles
7.1 SANOFI
7.1.1 SANOFI Corporate Summary
7.1.2 SANOFI Business Overview
7.1.3 SANOFI Non-Cancerous Blood Disease Treatment Major Product Offerings
7.1.4 SANOFI Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.1.5 SANOFI Key News
7.2 Novo Nordisk A/S
7.2.1 Novo Nordisk A/S Corporate Summary
7.2.2 Novo Nordisk A/S Business Overview
7.2.3 Novo Nordisk A/S Non-Cancerous Blood Disease Treatment Major Product Offerings
7.2.4 Novo Nordisk A/S Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.2.5 Novo Nordisk A/S Key News
7.3 Novartis AG
7.3.1 Novartis AG Corporate Summary
7.3.2 Novartis AG Business Overview
7.3.3 Novartis AG Non-Cancerous Blood Disease Treatment Major Product Offerings
7.3.4 Novartis AG Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.3.5 Novartis AG Key News
7.4 Pfizer Inc.
7.4.1 Pfizer Inc. Corporate Summary
7.4.2 Pfizer Inc. Business Overview
7.4.3 Pfizer Inc. Non-Cancerous Blood Disease Treatment Major Product Offerings
7.4.4 Pfizer Inc. Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.4.5 Pfizer Inc. Key News
7.5 Amgen Inc.
7.5.1 Amgen Inc. Corporate Summary
7.5.2 Amgen Inc. Business Overview
7.5.3 Amgen Inc. Non-Cancerous Blood Disease Treatment Major Product Offerings
7.5.4 Amgen Inc. Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.5.5 Amgen Inc. Key News
7.6 Alexion Pharmaceuticals, Inc.
7.6.1 Alexion Pharmaceuticals, Inc. Corporate Summary
7.6.2 Alexion Pharmaceuticals, Inc. Business Overview
7.6.3 Alexion Pharmaceuticals, Inc. Non-Cancerous Blood Disease Treatment Major Product Offerings
7.6.4 Alexion Pharmaceuticals, Inc. Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.6.5 Alexion Pharmaceuticals, Inc. Key News
7.7 Bayer AG
7.7.1 Bayer AG Corporate Summary
7.7.2 Bayer AG Business Overview
7.7.3 Bayer AG Non-Cancerous Blood Disease Treatment Major Product Offerings
7.7.4 Bayer AG Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.7.5 Bayer AG Key News
7.8 Bristol Myers Squibb Company
7.8.1 Bristol Myers Squibb Company Corporate Summary
7.8.2 Bristol Myers Squibb Company Business Overview
7.8.3 Bristol Myers Squibb Company Non-Cancerous Blood Disease Treatment Major Product Offerings
7.8.4 Bristol Myers Squibb Company Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.8.5 Bristol Myers Squibb Company Key News
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 F. Hoffmann-La Roche Ltd. Corporate Summary
7.9.2 F. Hoffmann-La Roche Ltd. Business Overview
7.9.3 F. Hoffmann-La Roche Ltd. Non-Cancerous Blood Disease Treatment Major Product Offerings
7.9.4 F. Hoffmann-La Roche Ltd. Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.9.5 F. Hoffmann-La Roche Ltd. Key News
7.10 Takeda Pharmaceutical Company Limited
7.10.1 Takeda Pharmaceutical Company Limited Corporate Summary
7.10.2 Takeda Pharmaceutical Company Limited Business Overview
7.10.3 Takeda Pharmaceutical Company Limited Non-Cancerous Blood Disease Treatment Major Product Offerings
7.10.4 Takeda Pharmaceutical Company Limited Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.10.5 Takeda Pharmaceutical Company Limited Key News
7.11 CSL Behring
7.11.1 CSL Behring Corporate Summary
7.11.2 CSL Behring Business Overview
7.11.3 CSL Behring Non-Cancerous Blood Disease Treatment Major Product Offerings
7.11.4 CSL Behring Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.11.5 CSL Behring Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-Cancerous Blood Disease Treatment Market Opportunities & Trends in Global Market
Table 2. Non-Cancerous Blood Disease Treatment Market Drivers in Global Market
Table 3. Non-Cancerous Blood Disease Treatment Market Restraints in Global Market
Table 4. Key Players of Non-Cancerous Blood Disease Treatment in Global Market
Table 5. Top Non-Cancerous Blood Disease Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-Cancerous Blood Disease Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-Cancerous Blood Disease Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-Cancerous Blood Disease Treatment Product Type
Table 9. List of Global Tier 1 Non-Cancerous Blood Disease Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Cancerous Blood Disease Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Non-Cancerous Blood Disease Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-Cancerous Blood Disease Treatment Revenue in Global (US$, Mn), 2023-2030
Table 14. By Application ? Global Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Non-Cancerous Blood Disease Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-Cancerous Blood Disease Treatment Revenue in Global (US$, Mn), 2023-2030
Table 17. By Region ? Global Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Non-Cancerous Blood Disease Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-Cancerous Blood Disease Treatment Revenue (US$, Mn), 2023-2030
Table 20. By Country - North America Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2023-2030
Table 22. By Country - Europe Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2023-2030
Table 24. By Region - Asia Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2023-2030
Table 26. By Country - South America Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2023-2030
Table 28. By Country - Middle East & Africa Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2023-2030
Table 30. SANOFI Corporate Summary
Table 31. SANOFI Non-Cancerous Blood Disease Treatment Product Offerings
Table 32. SANOFI Non-Cancerous Blood Disease Treatment Revenue (US$, Mn), (2018-2023)
Table 33. Novo Nordisk A/S Corporate Summary
Table 34. Novo Nordisk A/S Non-Cancerous Blood Disease Treatment Product Offerings
Table 35. Novo Nordisk A/S Non-Cancerous Blood Disease Treatment Revenue (US$, Mn), (2018-2023)
Table 36. Novartis AG Corporate Summary
Table 37. Novartis AG Non-Cancerous Blood Disease Treatment Product Offerings
Table 38. Novartis AG Non-Cancerous Blood Disease Treatment Revenue (US$, Mn), (2018-2023)
Table 39. Pfizer Inc. Corporate Summary
Table 40. Pfizer Inc. Non-Cancerous Blood Disease Treatment Product Offerings
Table 41. Pfizer Inc. Non-Cancerous Blood Disease Treatment Revenue (US$, Mn), (2018-2023)
Table 42. Amgen Inc. Corporate Summary
Table 43. Amgen Inc. Non-Cancerous Blood Disease Treatment Product Offerings
Table 44. Amgen Inc. Non-Cancerous Blood Disease Treatment Revenue (US$, Mn), (2018-2023)
Table 45. Alexion Pharmaceuticals, Inc. Corporate Summary
Table 46. Alexion Pharmaceuticals, Inc. Non-Cancerous Blood Disease Treatment Product Offerings
Table 47. Alexion Pharmaceuticals, Inc. Non-Cancerous Blood Disease Treatment Revenue (US$, Mn), (2018-2023)
Table 48. Bayer AG Corporate Summary
Table 49. Bayer AG Non-Cancerous Blood Disease Treatment Product Offerings
Table 50. Bayer AG Non-Cancerous Blood Disease Treatment Revenue (US$, Mn), (2018-2023)
Table 51. Bristol Myers Squibb Company Corporate Summary
Table 52. Bristol Myers Squibb Company Non-Cancerous Blood Disease Treatment Product Offerings
Table 53. Bristol Myers Squibb Company Non-Cancerous Blood Disease Treatment Revenue (US$, Mn), (2018-2023)
Table 54. F. Hoffmann-La Roche Ltd. Corporate Summary
Table 55. F. Hoffmann-La Roche Ltd. Non-Cancerous Blood Disease Treatment Product Offerings
Table 56. F. Hoffmann-La Roche Ltd. Non-Cancerous Blood Disease Treatment Revenue (US$, Mn), (2018-2023)
Table 57. Takeda Pharmaceutical Company Limited Corporate Summary
Table 58. Takeda Pharmaceutical Company Limited Non-Cancerous Blood Disease Treatment Product Offerings
Table 59. Takeda Pharmaceutical Company Limited Non-Cancerous Blood Disease Treatment Revenue (US$, Mn), (2018-2023)
Table 60. CSL Behring Corporate Summary
Table 61. CSL Behring Non-Cancerous Blood Disease Treatment Product Offerings
Table 62. CSL Behring Non-Cancerous Blood Disease Treatment Revenue (US$, Mn), (2018-2023)
List of Figures
Figure 1. Non-Cancerous Blood Disease Treatment Segment by Type in 2022
Figure 2. Non-Cancerous Blood Disease Treatment Segment by Application in 2022
Figure 3. Global Non-Cancerous Blood Disease Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-Cancerous Blood Disease Treatment Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Non-Cancerous Blood Disease Treatment Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Cancerous Blood Disease Treatment Revenue in 2022
Figure 8. By Type - Global Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2030
Figure 9. By Application - Global Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2030
Figure 10. By Region - Global Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2030
Figure 11. By Country - North America Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2030
Figure 12. US Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 13. Canada Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 14. Mexico Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 15. By Country - Europe Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2030
Figure 16. Germany Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 17. France Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 18. U.K. Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 19. Italy Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 20. Russia Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 21. Nordic Countries Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 22. Benelux Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 23. By Region - Asia Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2030
Figure 24. China Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 25. Japan Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 26. South Korea Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 27. Southeast Asia Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 28. India Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 29. By Country - South America Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2030
Figure 30. Brazil Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 31. Argentina Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 32. By Country - Middle East & Africa Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2030
Figure 33. Turkey Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 34. Israel Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 35. Saudi Arabia Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 36. UAE Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2030
Figure 37. SANOFI Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 38. Novo Nordisk A/S Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 39. Novartis AG Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 40. Pfizer Inc. Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 41. Amgen Inc. Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Alexion Pharmaceuticals, Inc. Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Bayer AG Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Bristol Myers Squibb Company Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. F. Hoffmann-La Roche Ltd. Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Takeda Pharmaceutical Company Limited Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. CSL Behring Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
